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Dysregulated lipid metabolism is a characteristic of
malignancies. Sterol regulatory element binding pro-
tein 1 (SREBP-1), a transcription factor playing a
central role in lipid metabolism, is highly activated in
malignancies. Here, we unraveled a link between
miR-29 and the SCAP (SREBP cleavage-activating
protein)/SREBP-1 pathway in glioblastoma (GBM)
growth. Epidermal growth factor receptor (EGFR)
signaling enhances miR-29 expression in GBM cells
via upregulation of SCAP/SREBP-1, andSREBP-1 ac-
tivatesmiR-29 expression via binding to specific sites
in its promoter. In turn, miR-29 inhibits SCAP and
SREBP-1 expression by interacting with their 30
UTRs.miR-29 transfection suppressed lipid synthesis
andGBMcell growth,whichwere rescuedby theaddi-
tion of fatty acids or N-terminal SREBP-1 expression.
Xenograft studies showed that miR-29 mimics signif-
icantly inhibit GBMgrowth and prolong the survival of
GBM-bearing mice. Our study reveals a previously
unrecognized negative feedback loop in SCAP/
SREBP-1 signalingmediated bymiR-29 and suggests
that miR-29 treatment may represent an effective
means to target GBM.INTRODUCTION
Regulation of lipid homeostasis is critical for cell growth and
function (Nohturfft and Zhang, 2009; van Meer et al., 2008). Ste-
rol regulatory element binding proteins (SREBPs), a family of
endoplasmic-reticulum (ER)-bound transcription factors, play a
central role in the synthesis of fatty acids, phospholipids, and
cholesterol (Goldstein et al., 2006; Jeon and Osborne, 2012;
Shao and Espenshade, 2012). There are two SREBP genes,
SREBF1 and SREBF2, in mammals. SREBF1 encodes two iso-Cell R
This is an open access article under the CC BY-Nforms, SREBP-1a and SREBP-1c, which differ in their first
exon and regulate fatty acid synthesis; SREBF2 encodes the
SREBP-2 protein, which mainly controls cholesterol synthesis
(Goldstein et al., 2006; Horton et al., 2002, 2003).
SREBPs are synthesized as inactive precursors and bind to
SREBP cleavage-activating protein (SCAP) in the ER membrane
(Goldstein et al., 2006). A large amount of evidence demon-
strates that SREBP activation is regulated by a sterol-mediated
negative feedback loop (Goldstein et al., 2006). High amounts
of cholesterol bind to SCAP and enhance its association with
the ER-resident protein, insulin-induced gene protein (Insig),
which retains the SCAP/SREBP complex in the ER (Adams
et al., 2004; Goldstein et al., 2006; Sun et al., 2007; Yang et al.,
2002). Intriguingly, a study from the Brown and Goldstein labora-
tory (Radhakrishnan et al., 2008) shows that a reduction in ER
cholesterol as low as 5% is sufficient to trigger the conforma-
tional change of SCAP and promote its dissociation from
Insig, allowing the COPII-complex-mediated vesicular transport
of SCAP/SREBP from the ER to the Golgi apparatus for sub-
sequent proteolytic SREBP activation (Goldstein et al., 2006;
Radhakrishnan et al., 2008; Sun et al., 2007). This study raises
the question of whether additional regulatory factors might
participate in SCAP/SREBP signaling in order to tightly control
lipid homeostasis.
Glioblastoma (GBM) is the most deadly primary brain tumor
(Bell and Guo, 2012; Guo et al., 2013, 2014; Ru et al., 2013;
Wen and Kesari, 2008). About 50% of GBM patients carry
mutated or amplified epidermal growth factor receptor (EGFR)
(Brennan et al., 2013; Furnari et al., 2015). Our recent studies
have demonstrated that oncogenic EGFR signaling activates
SREBP-1 and its regulated lipid synthesis and uptake pathways
via upregulation of SCAP to promote rapid GBM growth (Cheng
et al., 2015; Guo, 2016; Guo et al., 2009a, 2009b, 2011). How-
ever, the mechanisms by which cancer cells regulate lipid meta-
bolism in the context of constitutively activated oncogenic
signaling are still poorly understood.
Recently, several microRNAs (miRNAs), the small noncoding
RNAs that play an important role in the regulation of various
cellular processes including apoptosis, differentiation, andeports 16, 1527–1535, August 9, 2016 ª 2016 The Author(s). 1527
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
tumorigenesis (Schickel et al., 2008) have been reported to
participate in the regulation of lipid metabolism (Ferna´ndez-Her-
nando et al., 2011; Jeon et al., 2013). In particular, miR-29 has
been shown to suppress GBM cell growth in vitro when trans-
fected (Xu et al., 2015) and to connect with lipid metabolism
pathways in liver and hepatoma cells (Kurtz et al., 2014; Xu
et al., 2016). Thus, we asked whether miR-29 is involved in the
EGFR signaling-regulated SCAP/SREBP-1 pathway and GBM
tumor growth.
RESULTS
EGFR Signaling Promotes miR-29 Expression via
Upregulation of SCAP/SREBP-1
Our recent studies demonstrated that EGFR signaling upregu-
lates SCAP and activates SREBP-1 (Cheng et al., 2015; Guo,
2016; Guo et al., 2009b, 2011). Since miR-29 has been reported
to be involved in lipid metabolism (Kurtz et al., 2014; Xu et al.,
2016), we performed a correlation analysis between SREBF1
expression and miR-29 levels based on genomic EGFR status
in a large cohort of GBM patient samples (The Cancer Genome
Atlas [TCGA] database) (Cerami et al., 2012; Gao et al., 2013).
Interestingly, in GBM patients with altered EGFR (amplification
and/or mutation), the data show that expression of the three
members of the miR-29 family—miR-29a, -29b and -29c (Zhang
et al., 2012)—positively correlated with the expression of
SREBF1 (Figure 1A; Figure S1A). In contrast, no significant
correlation was observed in GBM patients with normal EGFR
(no amplification or mutation) (Figure S1B). These data suggest
that miR-29 is possibly involved in oncogenic EGFR-regulated
SREBP-1 signaling.
We then determined the intrinsic connection between EGFR
signaling, SCAP/SREBP-1 activation, and miR-29 expression
in GBM U87 cells that were stably expressing EGFR (U87/
EGFR) (Guo et al., 2009b). The data show that activating
EGFR/PI3K(phosphatidylinositol 3-kinase)/Akt signaling with
epidermal growth factor (EGF) significantly enhanced the
expression of pri-miR-29a/b1, -29b2/c, and mature miR-29a,
-29b, and -29c in a time-dependent manner (Figures 1B, 1C,
and S1C) (Zhang et al., 2012). As expected from our previous
reports, EGF stimulation strongly upregulated the SCAP pro-
tein levels and activated SREBP-1 (as assessed by the in-
creased N-terminal cleavage fragment of SREBP-1) (Figure 1C)
(Cheng et al., 2015; Guo et al., 2009b, 2011). Inhibition of
EGFR/PI3K/Akt signaling by their specific inhibitors significantly
reduced the levels of pri-miR-29a/b1, -29b2/c, and mature
miR-29 (Figures 1D and 1E) and downregulated the EGF stimu-
lation-enhanced SCAP protein levels and SREBP-1 cleavage
(Figure 1E).
We further investigated whether miR-29 expression induced
by EGFR signaling was mediated by SCAP/SREBP-1. The data
show that knockdown of SCAP or SREBP-1 with specific siRNA
(small interfering RNA) significantly reduced EGF-enhanced
expression of pri-miR-29a/b1, -29b2/c, and mature miR-29 (Fig-
ures 1F–1I). Moreover, to confirm that SCAP/SREBP-1 regulates
miR-29 expression in a physiological context, we examined the
direct effects of knockdown of SCAP or SREBP-1 on miR-29
expression in low-passage primary GBM83 cells, which are1528 Cell Reports 16, 1527–1535, August 9, 2016able to form GBM-like tumors in mouse brains, making it a
good orthotopic GBM xenograft model, as previously described
(Mao et al., 2013). The data show that knockdown of SCAP or
SREBP-1 significantly downregulated miR-29 expression in
GBM83 cells (Figures 1J–1M). Taken together, these data
demonstrate that SCAP/SREBP-1 regulates miR-29 expression.
SREBP-1 Functions as a Transcription Factor to
Promote miR-29 Expression
We wondered whether SREBP-1 regulates miR-29 expression
via its activity as a transcription factor. First, we examined the ef-
fects of expression of adenovirus-mediated N-terminal active
forms of SREBP-1a or -1c (nSREBP-1a or -1c) on miR-29
expression in U87 cells. The data show that overexpression of
nSREBP-1a or -1c strongly upregulated the expression of its
downstream targets, acetyl-coenzyme A (coA) carboxylase
(ACC), fatty acid synthase (FASN), and stearoyl-CoA desatur-
ase-1 (SCD1) (Figure 2A), and significantly promoted the expres-
sion of pri-miR-29 andmature miR-29 (Figure 2B). Moreover, our
data also show that upregulation of SREBP-1 by the liver X re-
ceptor (LXR) agonist GW3965 (Guo et al., 2011) significantly
enhanced the expression of miR-29 in U87 cells (Figure S2).
These data demonstrate that SREBP-1 regulates miR-29
expression.
Given that SREBP-1 is a transcription factor, we speculated
that it might bind to the promoter region of miR-29 to activate
its expression. As previously reported, miR-29a and miR-29b1
are located on chromosome 7q32 and share the same pro-
moter (miR-29a/b1), while miR-29b2 and miR-29c reside on
chromosome 1q32 and have a different promoter (miR-29b2/
c) (Figure S1C) (Zhang et al., 2012). We analyzed the promoter
regions of miR-29a/b1 and miR-29b2/c using the TFSEARCH
online promoter analysis tool and referring to the previous re-
ports of the DNA-binding motif for SREBP-1 (Seo et al., 2009;
Yang et al., 2014). Interestingly, four putative SREBP-1 bind-
ing sites, also named sterol regulatory element (SRE)-binding
sites (Seo et al., 2009), were found in the promoter of miR-
29a/b1 (Figure 2C, top), and one was found in the promoter
of miR-29b2/c (Figure 2D, top). We then examined whether
SREBP-1 directly binds to these SRE regions using a chro-
matin immunoprecipitation (ChIP) approach in GBM U87/
EGFR cells. As shown in Figures 2C and 2D, SREBP-1 directly
bound to SRE-1, SRE-2, and SRE-3/4 (a cross-linked region)
on the promoter of miR-29a/b1 (Figure 2C, middle and bot-
tom) and to the single SRE region on the promoter of miR-
29b2/c in U87/EGFR cells (Figure 2D, middle and bottom).
Moreover, EGF stimulation significantly enhanced the binding
of SREBP-1 to all SRE motifs of the miR-29 promoters (Fig-
ures 2C and 2D), which is consistent with the enhanced
miR-29 expression and increased nuclear form of SREBP-1
induced by EGF in U87/EGFR cells (Figures 1B and 1C). More-
over, the binding of SREBP-1 to the promoters of miR-29a/b1
and -29b2/c was confirmed by ChIP assay in the low-passage
primary GBM83 cells (Figures 2E and 2F). Taken together,
these data strongly support that SREBP-1 transcriptionally
regulates miR-29 expression.
We then examined the transcriptional activity of SREBP-1 on
miR-29 promoters using a promoter-driven luciferase (luc)
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Figure 1. EGFR Signaling Promotes miR-29 Expression via Upregulation of SCAP/SREBP-1
(A) Pearson correlation analysis of the expression of SREBF1 and miR-29 family (miR-29a, miR-29b, and miR-29c) in a large cohort of GBM patient tissues with
altered genomic EGFR (amplification and/or mutation, n = 132) from the TCGA database.
(B and C) Real-time PCR analysis of the levels of pri-miR29a/b1, pri-miR29b2/c, and mature miR-29 (mean ± SD) (B) or western blot analysis of the indicated
proteins (C) in U87/EGFR cells stimulated with EGF (50 ng/ml) at the indicated times after serum starvation for 24 hr. Statistical significance was determined by
Student’s t test (n = 3). *p < 0.001 compared with control cells without EGF stimulation (0 hr).
(D and E) Real-time PCR analysis of the levels of pri-miR29a/b1, pri-miR29b2/c, and mature miR-29 (mean ± SD) (D) or western blot analysis of the indicated
proteins (E) in U87/EGFR cells stimulated with EGF (50 ng/ml) for 12 hr after pre-treatment with various kinase inhibitors, i.e., erlotinib (Erloti, 10 mM) for EGFR,
BKM120 (BKM, 10 mM) for PI3K, and MK2206 (MK, 10 mM) for Akt, for 1 hr. Statistical significance was determined by Student’s t test (n = 3). #p < 0.05; +p < 0.01;
*p < 0.001.
(F and G) Western blot analysis of the indicated proteins (F) or real-time PCR analysis of pri-miR29a/b1, pri-miR29b2/c, and mature miR-29a/b/c (mean ± SD) (G)
in U87/EGFR cells stimulatedwith EGF (50 ng/ml) for 12 hr after knockdown of SCAPby specific siRNA. Statistical significancewas determined by Student’s t test
(n = 3). +p < 0.01; *p < 0.001. Ctrl, control.
(H and I) Western blot analysis of the indicated proteins (H) or real-time PCR analysis of pri-miR29a/b1, pri-miR29b2/c, andmature miR-29a/b/c (mean ± SD) (I) in
U87/EGFR cells stimulated with EGF (50 ng/ml) for 12 hr after knockdown of SREBP-1 by specific siRNA. Statistical significance was determined by Student’s t
test (n = 3). +p < 0.01; *p < 0.001.
(J–M) Western blot analysis of lysates (J and L) or real-time PCR analysis of pri-miR-29/mature miR-29 (mean ± SD) (K and M) from human primary GBM83 cells
after siRNA transfection (50 nM) against SCAP (J and K) or SREBP-1 (L and M) for 48 hr. Statistical significance was determined by Student’s t test. *p < 0.01
compared with scramble control si RNA (siControl) cells.
See also Figure S1.reporter system. As shown in Figures 2G and 2H, we cloned the
different fragments of the miR-29 promoters into the pGL3-luc
expression vector and transfected them into HEK293T cells
together with active nSREBP-1a or -1c plasmids. Consistentwith promoting miR-29 expression (Figure 2B), expression of
nSREBP-1a or -1c markedly enhanced the luc activity driven
by the full-length promoter of miR-29a/b1 or miR-29b2/c
(including all SRE binding sites) (Figures 2G and 2H). DeletionCell Reports 16, 1527–1535, August 9, 2016 1529
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Figure 2. SREBP-1 Functions as a Transcription Factor to Promote miR-29 Expression
(A) Western blot analysis of U87 cells after infection with the adenovirus (Ad) expressing the N-terminal SREBP-1a or -1c (nSREBP-1a or -1c) for 48 hr.
(B) Real-time PCR analysis of the expression of pri-miR29a/b1, pri-miR29b2/c (top), and mature miR-29 (bottom) in U87 cells after infection with the adenovirus
expressing the N-terminal form of SREBP-1a or -1c (nSREBP-1a or -1c) for 48 hr (mean ± SD). Statistical significance was determined by Student’s t test (n = 3).
*p < 0.001.
(C and D) Schemas at the top show putative SREBP-1 binding sites (SREs) on miR-29a/b1 (C, top) or miR-29b2/c promoter (D, top). Agarose gel electrophoresis
of PCR products after chromatin immunoprecipitation (ChIP) assay using immunoglobulin G (IgG) or anti-SREBP-1 antibody in U87/EGFR cells with or without
EGF (50 ng/ml) stimulation for 12 hr (C and D, middle). The PCR products of the ChIP assay shown on the agarose gel were quantified by ImageJ and normalized
with the value of the input without EGF stimulation (C and D, bottom) (mean ± SD). Statistical significance was determined by Student’s t test (n = 3). #p < 0.05;
+p < 0.01; *p < 0.001.
(E and F) PCR analysis of SREBP-1 binding to the specific SRE motifs located in pri-miR-29a/b1 (E) or pri-miR-29b2/c promoter (F) in primary GBM83 cells. The
PCR products of the ChIP assay shown on the agarose gel were quantified by the ImageJ software and normalized with the value of the input (mean ± SD).
Statistical significance was determined by an unpaired Student’s t test (n = 3). *p < 0.01.
(G and H) Luc activity analysis of the promoters of miR-29a/b1 (G) or miR-29b2/c (H) with different deletions of SRE binding sites cloned in the pGL3-basic vector
that were transfected into HEK293T cells together with Renilla and PC3.1, nSREBP-1a or -1c plasmids for 48 hr (mean ± SD). Statistical significance was
determined by Student’s t test (n = 3). +p < 0.01; *p < 0.001; N.S, no significance.
See also Figure S2.of the SRE binding sites in the promoter of miR-29a/b1 or
-29b2/c significantly decreased nSREBP-1-enhanced luc activ-
ity, which was reduced to the levels of the control vector (empty
PC3.1 plasmid) transfection when all SRE binding sites were
removed (Figures 2G and 2H), demonstrating that SREBP-1
directly activates miR-29 expression via binding to the specific
SRE motifs in its promoters.1530 Cell Reports 16, 1527–1535, August 9, 2016miR-29 Reversely Inhibits SCAP and SREBP-1
Expression via Binding to Their 30 UTR
To explore the function of miR-29 in GBM, we searched the po-
tential targets of miR-29 by using microRNA.org (http://www.
microrna.org) and miRBase (http://www.mirbase.org) prediction
resources. Interestingly, all members of the miR-29 family (-29a,
-29b, or -29c) have the same putative targeting site in the 30 UTR
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Figure 3. miR-29 Reversely Inhibits SCAP and SREBP-1 Expression through Binding to Their 30 UTR
(A andB) Schemas (top) and luc activity analysis of putativemiR-29 binding to the 30 UTRofSCAP (A) orSREBF1 (B) in HEK293T cells transfected with pmirReport
vector carrying the wild-type (WT) or mutant (MT) 30 UTR together with miR-29 (50 nM) and renilla. The luc activity of each sample was normalized with the control
transfected with wild-type 30 UTR vector (mean ± SD) (bottom). Statistical significance was determined by Student’s t test (n = 3). #p < 0.01; *p < 0.001, compared
with scramble control miRNA (Ctrl miR) transfection with wild-type SCAP or SREBF1 30 UTR.
(C and D) Western blot analysis of the indicated proteins (C) or real-time PCR analysis of gene expression (mean ± SD) (D) for GBM cells transfected with miR-29
(50 nM) for 48 hr. Statistical significance was determined by Student’s t test (n = 3). #p < 0.01; or *p < 0.001, compared with scramble control miRNA (Ctrl miR)
transfection.
See also Figure S3.of SCAP or SREBF1mRNA (Figures 3A and 3B, top). We cloned
the 30 UTR of SCAP or SREBF1 into a luc reporter vector and
examined the effects of its interaction with miR-29 on luc activity
in HEK293T cells. As shown in Figures 3A and 3B, miR-29 trans-
fection significantly reduced the activity of luc that was linked
with the wild-type 30 UTR of SCAP or SREBF1, and the reduction
was completely abolished when the targeting site on the 30 UTR
was mutated, suggesting that miR-29 inhibits SCAP or SREBF1
expression via direct binding to their 30 UTR.
We then examined the effects of miR-29 on SCAP and
SREBP-1 expression by analyzing their protein andmRNA levels
in various GBM cell lines and patient-derived cells (i.e., GBM83
cells) after transfection with miR-29. Western blot analysis
demonstrated that miR-29 transfection markedly reduced the
protein levels of SCAP and SREBP-1 (Figure 3C). Moreover,real-time PCR analysis showed that miR-29 transfection signifi-
cantly reduced the expression of SCAP, SREBF1, SREBP-1a,
and -1c (Figure S3) and downregulated the expression of their
targets, ACACA, FASN, LDLR, and SCD1, which control de
novo fatty acid synthesis (Figure 3D).
Collectively, these data demonstrate that miR-29 serves as a
negative regulator, inhibiting SCAP/SREBP-1 and the lipid syn-
thesis pathway in GBM cells.
miR-29 Inhibits GBM Growth In Vitro and In Vivo via
Suppressing SCAP/SREBP-1
Next, we examined whether miR-29 suppressed de novo lipid
synthesis, in line with its inhibitory effects on SCAP/SREBP-1
signaling (Figure 3). Radiolabeled 14C-glucose was added to
the culture medium of U87 cells after transfection with miR-29.Cell Reports 16, 1527–1535, August 9, 2016 1531
As shown in Figure 4A, miR-29 significantly inhibited the produc-
tion of 14C-labeled lipids generated from 14C-glucose. These
data were confirmed by thin-layer chromatography analysis,
which showed that miR-29 transfection significantly reduced
the levels of free fatty acids (FFAs) and triglycerides (TGs) in
GBM cells compared to control cells transfected with scramble
miRNA (Figures S4A and S4B).
Our previous studies have revealed that GBM growth is highly
dependent on SCAP/SREBP-1 signaling (Cheng et al., 2015;
Geng et al., 2016; Guo et al., 2009b, 2011). We asked whether
miR-29 transfection was able to inhibit GBM cell growth through
suppressing SCAP/SREBP-1-regulated lipogenesis. As shown
in Figures 4B and S4C, transfection with miR-29 markedly in-
hibited GBM cell growth, which was significantly rescued by
the overexpression of nSREBP-1a or -1c. Moreover, addition
of the fatty acids palmitate (PA) and oleic acid (OA), two major
products of the fatty acid synthesis pathway regulated by
SCAP/SREBP-1 (Horton et al., 2002), markedly rescued miR-
29-mediated growth inhibition in various GBM cell lines and
GBMpatient-derived cells (GBM83) (Figures 4C and S4D). These
data strongly demonstrate thatmiR-29 transfection inhibits GBM
growth through suppressing SREBP-1 expression and down-
stream lipogenesis.
Next, we used a xenograft mouse model in which U87/
EGFRvIII-luc cells that stably expresses luc were stereotacti-
cally implanted into mouse brain in order to examine the in vivo
antitumor effects of miR-29 using bioluminescence imaging
(Cheng et al., 2015). The data show that transfecting miR-29
into U87/EGFRvIII-luc cells markedly inhibited GBM tumor
growth in the mouse brains, as shown by luminescent imaging
(Figure 4D), and suppressed the expression of SCAP and
SREBP-1 in the GBM tumor tissues from U87/EGFRvIII-luc-
bearing mice (Figure 4E, left; Figure S4E). Consistent with
the intracranial tumor growth, Kaplan-Meier analysis showed
that miR-29 transfection significantly prolonged the overall
survival of U87/EGFRvIII-luc-bearing mice (Figure 4F, left).
These data were further confirmed in the primary GBM83-
cell-generated intracranial mouse model. The data show that
miR-29 transfection significantly reduced the expression of
SCAP and SREBP-1 in tumor tissues (Figure 4E, right, and
S4E) and prolonged the overall survival of GBM83-bearing
mice (Figure 4F, right).
DISCUSSION
Lipids are critical cellular components, and their alteration leads
to various metabolic diseases such as atherosclerosis and
obesity (Nohturfft and Zhang, 2009; van Meer et al., 2008).
Recent evidence shows that lipid metabolism is also reprog-
rammed in malignancies to support rapid tumor growth (Bell
and Guo, 2012; Geng et al., 2016; Guo et al., 2013, 2014; Menen-
dez and Lupu, 2007; Ru et al., 2013). In particular, our re-
cent work has revealed that oncogenic EGFR signaling activates
lipid metabolism via upregulation of SCAP/SREBP-1 signaling
(Cheng et al., 2015; Guo, 2016; Guo et al., 2009b, 2011). Thus,
a better understanding of how lipidmetabolism is reprogrammed
in cancer cells may lead to development of promising strategies
to treat malignancies.1532 Cell Reports 16, 1527–1535, August 9, 2016miR-29 has previously been reported to function as a tumor
suppressor by suppressing different oncogenes involved in
methylation, apoptosis, and metastasis pathways (Fabbri et al.,
2007; Ru et al., 2012; Schickel et al., 2008; Zhang et al., 2012).
Our study does not exclude the possibility that these miR-29 anti-
tumor functions play a role inGBM.Nevertheless, in this study,we
unraveled a previously unappreciated critical function of miR-29
in the regulation of lipidmetabolismand identified a previously un-
recognized negative feedback loopmediated bymiR-29 in SCAP/
SREBP-1 signaling (Figure 4G). We found that EGFR signaling
enhanced miR-29 expression via upregulation of SCAP/SREBP-
1 expression, with SREBP-1 transcriptionally activating specific
SRE motifs in the promoter of miR-29. Interestingly, miR-29
inversely suppresses SCAP and SREBP-1 expression by binding
to their 30 UTR regions. These data demonstrate that a multilayer
of regulatory mechanisms converges on the regulation of the
SCAP/SREBP-1 pathway (Figure 4G).
Although the role of SCAP/SREBP-1 in lipogenesis is well
established (Goldstein et al., 2006; Guo et al., 2014), its pre-
cise regulation in malignancies is still poorly understood. Our
present study provides a molecular link between EGFR
signaling, miR-29, and SCAP/SREBP-1, demonstrating an
elaborate feedback loop operating in cancer cells to regulate
lipid synthesis driven by oncogenic signaling. The addition of
fatty acids or the expression of active N-terminal SREBP-1
rescued miR-29-inhibited GBM cell growth, demonstrating
that decreased lipogenesis underlies the mechanism of
miR-29-mediated GBM growth suppression. Moreover, the
increased survival in mice implanted with GBM cells trans-
fected with miR-29 suggests that suppressing SCAP and
SREBP-1 with miR-29 provides an effective means to target
malignancies and other metabolic syndromes. Analyzing
further the levels and distribution of miR-29 in normal brain tis-
sues versus tumor tissues will be important for designing a
better strategy to treat GBM.
Although SREBP-1, a master transcription factor in lipid meta-
bolism, was identified over 20 years ago (Wang et al., 1994), no
targeting pharmaceutics have been developed so far. Using
miR-29 mimics to inhibit this central pathway controlling lipid
metabolism may be a promising strategy to suppress GBM
growth. Additional studies should also be dedicated to the devel-
opment of effective methods to deliver the miR-29 mimics into
brain tumor tissues.
EXPERIMENTAL PROCEDURES
Analysis of GBM Patient Tumor Tissues
TCGA mRNA (Affymetrix, u133a) and miRNA expression (Agilent, 8X15k) data
for GBMpatient tumor tissues were downloaded through the TCGA data portal
(http://cancergenome.nih.gov/; updated December 2014), and the patients’
EGFR status information (alteration: amplification or mutation, n = 132; normal
EGFR: no amplification or mutation, n = 97) was obtained from the cBioPortal
for Cancer Genomics (http://www.cbioportal.org/) (Cerami et al., 2012; Gao
et al., 2013). The association between the expression of SREBF1 and miR-
29 was evaluated by the Pearson correlation method. Data analyses were per-
formed with SAS 9.4 (SAS).
Cell Culture and Vectors
Human GBM cell lines, i.e., U87, U87/EGFRvIII, U87/EGFRvIII-luc, U87/EGFR,
U251, T98, and the HEK293T cell line were cultured in DMEM (Cellgro)
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Figure 4. miR-29 Inhibits GBM Growth via Suppressing SCAP/SREBP-1
(A) Analysis of radiolabeled lipid products by scintillation counting for U87 cells in culture with 14C-glucose for 2 hr after transfection with miR-29 or scramble
control miRNA (50 nM) for 48 hr (mean ± SD). Statistical significance was determined by Student’s t test (n = 5). #p < 0.05; *p < 0.001, compared with scramble
control miRNA (Ctrl miR) transfection.
(B) Growth analysis of U87 cells transfected with miR-29 or scramble control miRNA (50 nM) overnight and then infected with the adenovirus (Ad) constitutively
expressing nSREBP-1a or -1c in 1% LPDS (lipoprotein-depleted serum) media for 3 days. Cell number was counted after trypan blue staining (mean ± SD).
Statistical significance was determined by Student’s t test (n = 3). *p < 0.001 for comparison with scramble control miRNA (Ctrl miR) transfection; #p < 0.01 for the
indicated comparison group.
(C) Growth analysis of GBM cells transfected with miR-29 or scramble control miRNA (50 nM) in the presence or absence of palmitate (PA, 10 mM) and oleic acid
(OA, 10 mM) in 1%LPDSmedia for 3 days (U87, T98, andU251 cells) or neurobasal medium (GBM83 cells) for 2 days. Cells were counted after trypan blue staining
(mean ± SD). Statistical significance was determined by Student’s t test (n = 3). *p < 0.001 for comparison with scramble control miRNA (Ctrl miR) transfection;
#p < 0.001 for the indicated comparison group.
(D) Luminescence imaging of GBM tumor growth in mouse brains at day 14 post-intracranial implantation of 13 105 U87/EGFRvIII-luc cells after transfection with
miR-29 or scramble control miRNA (50 nM) for 48 hr (top). Bottom shows the quantification of the luminescence signal intensity from intracranial tumor on day 14
(mean ± SEM). Statistical significance was determined by Student’s t test (n = 7). *p < 0.001 for comparison with scramble control miRNA (Ctrl miR) transfection.
p/s, photons per second.
(E) Immunohistochemistry analysis of SCAP and SREBP-1 protein levels in intracranial tumor tissues fromU87/EGFRvIII-bearing mice transfected with miR-29 at
day 20 or scramble control miRNA at day 15 (left) or from human primary GBM83-bearing mice transfected with miR-29 or control miRNA at day 14 (right). Bottom
show the relative protein levels in tumor tissues quantified by ImageJ and averaged from five separate areas in each tumor. The results were normalized with
control miRNA tumors (mean ± SEM; n = 5). Statistical significance was determined by Student’s t test. *p < 0.001 for comparison with scramble control miRNA
transfection. Scale bars, 50 mm.
(F) Kaplan-Meier analysis of GBM-bearing mice implanted with 1 3 105 U87/EGFRvIII cells (left) or 2 3 104 GBM83 cells (right) after transfection with miR-29 or
scramble control miRNA (50 nM) for 48 hr. Statistical significance was determined by log-rank test (n = 7).
(G) Schematic model of the previously unrecognized negative feedback loop regulating lipid metabolism and associated tumor growth. EGFR signaling promotes
miR-29 expression via upregulation of SCAP/SREBP-1, and SREBP-1 functions as a transcription factor to activate miR-29 transcription. In turn, miR-29
reversely inhibits SCAP and SREBP-1 expression via directly binding to their 30 UTR to modulate tumor growth.
See also Figure S4.
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supplemented with 5% fetal bovine serum (FBS) (Gemini Bio-Products). The
GBM patient-derived cells, GBM83, which were previously molecularly char-
acterized and described (Mao et al., 2013), were cultured in neurobasal me-
dium supplemented with B-27 (13), heparin (2 mg/ml), EGF (50 ng/ml), and
fibroblast growth factor (FGF; 50 ng/ml) in a humidified atmosphere of 5%
CO2, 95%air at 37
C. U87/EGFRvIII cells were generated by stably expressing
EGFRvIII, a constitutively active mutant form of EGFR, in U87 cells (Guo et al.,
2009a). U87/EGFRvIII-luc cells stably express luc (Cheng et al., 2015). U87/
EGFR cells were generated by retrovirus-mediated transduction of wild-type
EGFR into U87 cells, followed by selection of stable clones (Guo et al.,
2009b). pcDNA3.1-2xFLAG-SREBP-1a and -1c (N-terminal fragments) were
a gift from Dr. Timothy Osborne (Addgene plasmids #26801 and #26802)
(Toth et al., 2004). Adenovirus containing N-terminal SREBP-1a or -1c was
produced and amplified as previously described (Dif et al., 2006).
ChIP Assay
The details of the ChIP assay are described in the Supplemental Experimental
Procedures.
Real-Time RT-PCR
Details are described in the Supplemental Experimental Procedures.
30 UTR Luc Assay
Details are described in the Supplemental Experimental Procedures.
Promoter Luc Assay
Details are described in the Supplemental Experimental Procedures.
Intracranial Mouse Model and Survival
Female athymic nude mice (6–8 weeks of age, obtained from Target Validation
Shared Resource at the Ohio State University (OSU) James Comprehensive
Cancer Center that are originally received from the National Cancer Institute)
were used for the intracranial xenograft models. Cells (1 3 105 U87/EGFRvIII-
luc or 23 104 GBM83 cells in 4 ml PBS), after transfection with miR-29 or mimic
control for 48 hr, were stereotactically implanted into mouse brain. Mice were
then observed until they becamemoribund, at which point they were sacrificed.
All animal procedureswere approved by theSubcommittee onResearch Animal
Care at the OSU Medical Center.
Mouse Bioluminescence Imaging
Analysis of mouse intracranial tumor by bioluminescence imaging was per-
formed as previously described (Cheng et al., 2015). Imaging experiments
were conducted at the OSU Small Animal Imaging Core.
Statistical Analysis
Statistical analysis was performed with Excel or GraphPad Prism5. The
matched samples were compared using paired Student’s t test, and
samples between treatments were compared by using two-sample t tests.
Kaplan-Meier plots were used for analysis of mouse overall survival (signif-
icance was analyzed by log-rank test). A p value < 0.05 was considered
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.07.017.
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